Mechanism of Action

Non-peptide GLP-1 receptor agonist. Improves glucose control, reduces appetite, supports weight loss via GLP-1 receptor pathway without peptide absorption constraints. Oral, once-daily administration.

Clinical Use

Chronic weight management (FDA-approved, Foundayo). T2D management (Phase 3 complete, approval pending).

Contraindications

GI adverse events consistent with GLP-1 class (nausea, vomiting, diarrhea). Full long-term safety profile still being established via post-marketing surveillance.

Evidence Summary

FDA approved April 2026 (Foundayo) for obesity. Phase 3 T2D data shows superiority over oral semaglutide 14mg.

Key Studies
  • 1.Phase 2 Obesity, NEJM 2023 — placebo-adjusted weight loss 9.4-14.7% depending on dose at 36 weeks. Multi-dose Phase II RCT
  • 2.Phase 3 Obesity (ATTAIN-1), Eli Lilly 2026 — average 27-pound loss at highest dose. Supported FDA approval for obesity
  • 3.Phase 3 T2D (ACHIEVE-3) — A1C reduction 2.2% vs 1.4% for oral semaglutide 14mg. Superiority demonstrated
Evidence Gaps

Less long-term real-world exposure than legacy GLP-1 agents. Much Phase 3 detail from company press releases vs full journal publications. Durability and discontinuation effects still being characterized.

Emerging Research

Obstructive sleep apnea, hypertension, knee osteoarthritis, cardiovascular outcomes trials ongoing.

iRemedy Sourcing Status
RESEARCH / INVESTIGATIONAL
Small-molecule (non-peptide) — compounding API availability subject to evolving regulatory guidance

iRemedy is a 50-state licensed, NABP-accredited wholesale distributor. Peptides supplied with full CoA, DSCSA serialization, and UPS Healthcare cold chain logistics. Wholesale to licensed healthcare facilities and compounding pharmacies only.

← Back to Peptide Library ← Previous: Octreotide Next: Oxytocin →
Request Peptide Catalog →